Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902).
Evanthia Galanis
No relevant relationships to disclose
S. Keith Anderson
No relevant relationships to disclose
C. Ryan Miller
No relevant relationships to disclose
Jann Nagina Sarkaria
Research Funding - Basilea; Genetic Technologies; Merck; Sanofi
Kurt A. Jaeckle
No relevant relationships to disclose
Jan C. Buckner
No relevant relationships to disclose
Keith L. Ligon
No relevant relationships to disclose
Karla V. Ballman
No relevant relationships to disclose
Dennis Frederic Moore
No relevant relationships to disclose
Manmeet Singh Ahluwalia
Honoraria - Merck
Eudocia Quant Lee
No relevant relationships to disclose
Elizabeth Robins Gerstner
No relevant relationships to disclose
Glenn Jay Lesser
Honoraria - Merck
Michael Prados
No relevant relationships to disclose
Stuart A. Grossman
No relevant relationships to disclose
Caterina Giannini
No relevant relationships to disclose
Patrick Y. Wen
No relevant relationships to disclose